CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc., today announced that Xanafide® (amonafide malate) has been granted Orphan Drug Designation by the European Commission for the treatment of acute myeloid leukemia (AML). In December 2006, the United States Food and Drug Administration (FDA) awarded Orphan Drug Designation to Xanafide for the treatment of AML. Xanafide is currently in a pivotal Phase 3 trial in patients with secondary AML under a Special Protocol Assessment with the FDA.
